E

Evolution Research Group | Behavioral Research Specialists, LLC

Research site
(Unclaimed)
Location
230 N. Maryland Avenue, Suite 207, Glendale, California, United States of America
Site insights

Top conditions

Depression (18 trials)

Depressive Disorder (18 trials)

Major Depressive Disorder (16 trials)

Schizophrenia (5 trials)

Alzheimer Disease (3 trials)

Top treatments

Rapastinel
Vilazodone
Brexpiprazole
Cariprazine
Lurasidone
Divalproex
AVP-786
Lithium
Eszopiclone
Aticaprant

Parent organization

This site is a part of Evolution Research Group

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

6 of 42
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-1)

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Drug: Aticaprant
Other: Placebo

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:Is SNK01...

Enrolling
Moderate Alzheimer Disease
Other: Placebo
Biological: SNK01

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

Trial sponsors

Allergan logo

Allergan (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems